| Industry | Status | Date | Ticker(s) | issuer(s) | MO | SP | FI | Size (M) | Ranking | TNR | Call | MTY | Coupon | Leads | product | Region | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HLTH | PRCD | Aug 27, 2026 | GSK | GSK Capital BV | A2 | A | - | €850 | Sr. Unsecured | 1.50 | - | Mar-28 | 3mEu+30 | IGC | EMEA | ||||
HLTH | PRCD | Aug 27, 2026 | GSK | GSK Capital BV | A2 | A | - | €1,000 | Sr. Unsecured | 4.00 | - | Sep-30 | 3.50% | IGC | EMEA | ||||
HLTH | PRCD | Aug 27, 2026 | GSK | GSK Capital BV | A2 | A | - | €850 | Sr. Unsecured | 8.00 | - | Sep-34 | 3.875% | IGC | EMEA | ||||
HLTH | PRCD | Aug 27, 2026 | GSK | GSK Capital BV | A2 | A | - | €800 | Sr. Unsecured | 11.00 | - | Sep-37 | 4.125% | IGC | EMEA | ||||
HLTH | PRCD | Aug 24, 2026 | AZN | AstraZeneca Finance LLC | A1 | A+ | - | €700 | Sr. Unsecured | 3.50 | - | Mar-30 | 3.402% | IGC | EMEA | ||||
HLTH | PRCD | Aug 24, 2026 | AZN | AstraZeneca Finance LLC | A1 | A+ | - | €600 | Sr. Unsecured | 6.00 | - | Sep-32 | 3.652% | IGC | EMEA | ||||
HLTH | PRCD | Aug 24, 2026 | AZN | AstraZeneca Finance LLC | A1 | A+ | - | €500 | Sr. Unsecured | 9.00 | - | Sep-35 | 3.923% | IGC | EMEA | ||||
HLTH | PRCD | Aug 24, 2026 | AZN | AstraZeneca Finance LLC | A1 | A+ | - | €750 | Sr. Unsecured | 12.00 | - | Sep-38 | 4.169% | IGC | EMEA | ||||
HLTH | PRCD | Aug 10, 2026 | ROSW | Roche Kapitalmarkt AG | Aa2 | AA | AA | CHF365 | Sr. Unsecured | 5.25 | - | Nov-31 | 0.7812% | IGC | EMEA | ||||
HLTH | PRCD | Aug 10, 2026 | ROSW | Roche Kapitalmarkt AG | Aa2 | AA | AA | CHF410 | Sr. Unsecured | 10.00 | - | Aug-36 | 1.095% | IGC | EMEA |